Schering-Plough

Global Poultry Healthcare Market Research Report 2022: Focus on Vaccines, Parasiticides, Anti-Infectives, & Medical Feed Additives - Forecasts to 2026 & 2031 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 9, 2022
Manufacturing, Health, Pharmaceutical, Pets, Agriculture, Other Science, Natural Resources, Research, Science, Veterinary, Chemicals, Plastics, Livestock, Parasitism, Infectious bursal disease, Prevalence, PCR, Marek's disease, Vaccine, HPAI, Chicken, Seafood, Boehringer Ingelheim, Risk, Poultry, Merck, Human alphaherpesvirus 1, ELISA, Disease, Solution, World Organisation for Animal Health, Meat, IdentiGEN, Schering-Plough, Public health, Growth, Infection, Animal, Acquisition, House, Aquaculture

The poultry healthcare market covered in this report is segmented by product into vaccines; parasiticides; anti-infectives; and medical feed additives.

Key Points: 
  • The poultry healthcare market covered in this report is segmented by product into vaccines; parasiticides; anti-infectives; and medical feed additives.
  • Medical feed additive is a feed additive which is an additive of extra nutrients or drugs for livestock.
  • The increasing prevalence of disease outbreaks in poultry animals is expected to propel the growth of the poultry healthcare market.
  • IdentiGEN is an Ireland-based poultry healthcare company that provides DNA-based solutions for producers, processors, and retailers of meat, poultry, and seafood products.

Life Sciences C-Suite Leaders To Explore "Reinventing Life Sciences Leadership" at January Vanguard Forum in Cambridge

Retrieved on: 
Wednesday, November 9, 2022
Industry, Chief executive officer, Technology, The Vanguard Group, Schering-Plough, NEW, Economics, Vanguard, Forum, GC, Leadership, Perception, HBR, Management, Tenneco, United Airlines, Walgreens

NEW YORK, Nov. 9, 2022 /PRNewswire-PRWeb/ -- The Vanguard Network today announced its annual Life Sciences leadership Forum on January 23 in Cambridge, MA. The event marks a return to face-to-face Vanguard events for C-Suite life sciences and healthcare leaders.

Key Points: 
  • Life Sciences leaders to gather in Cambridge, MA for a confidential, highly-interactive looks at the future of the industry.
  • NEW YORK, Nov. 9, 2022 /PRNewswire-PRWeb/ -- The Vanguard Network today announced its annual Life Sciences leadership Forum on January 23 in Cambridge, MA.
  • The event marks a return to face-to-face Vanguard events for C-Suite life sciences and healthcare leaders.
  • The day-long Forum includes confidential, highly interactive sessions designed to reflect the real-life challenges facing today's life sciences executives.

Mirati Therapeutics Appoints Alan Sandler, M.D., as Executive Vice President and Chief Medical Officer, Shares Update to Executive Leadership Team

Retrieved on: 
Tuesday, November 8, 2022
Oregon Health and Science University Center for Women's Health, NASDAQ, Lung cancer, Judgement, U.S. Securities and Exchange Commission, Industry, Patient, SEC, TAM, Company, Ponce Health Sciences University, SAN, Board, Cancer, Director, Schering-Plough, Internal medicine, Oregon Health & Science University, Life, Drug discovery, Drug development, Stanford University, 2021 Essex County Council election, R&D, SOS1, Pfizer, Medical college, Hoffmann-La Roche, Oncology, Vanderbilt University, Head, Science, Leadership, Genentech, Indiana University, PRMT5, Health, Research, Therapy, MTA, Management, Pharmaceutical industry, Mirati

SAN DIEGO, Nov. 8, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the appointment of Alan Sandler, M.D., to the position of executive vice president and chief medical officer. In his role, Dr. Sandler will provide leadership and direction over clinical development and operations, regulatory affairs, drug safety and asset development strategy and report to David Meek, chief executive officer. As part of the transition, Dr. James Christensen, executive vice president and chief scientific officer, will also report to Mr. Meek.

Key Points: 
  • As part of the transition, Dr. James Christensen, executive vice president and chief scientific officer, will also report to Mr. Meek.
  • "His extensive experience in drug development, including clinical development experience with adagrasib, will augment our executive leadership at this pivotal time for Mirati.
  • Most recently, Dr. Sandler was president and global head of oncology for Zai Lab where he led global oncology development for the company.
  • He joins Mirati with over 30 years of oncology and drug development experience across industry and academia.

HEMANEXT ANNOUNCES CLOSE OF SERIES B EQUITY FUNDING ROUND

Retrieved on: 
Monday, November 7, 2022
O2, Company, LR, Research, Exercise, CO2, Red blood cell, Merck, Board, Biotechnology, RBC, White blood cell, FDA, Safety, Ness, University of Cape Town, Johns Hopkins University, National, University, Division, CEO, Collection, UCB, Drug development, Board of directors, Transfusion medicine, Technology, Patient, Schering-Plough, University of Cambridge, Management, Pharmaceutical industry, Medical device, Nordic, Director, Medicine

LEXINGTON, Mass., Nov. 7, 2022 /PRNewswire/ -- Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, today announced the successful first close of its Series B fundraising round. Taken together with the exercise of outstanding warrants, this close brings an additional $18 million of equity capital from noted global private investors with deep finance and healthcare expertise. To date, the company has raised approximately $130mm (inclusive of $8mm in grant funding from the National Institutes of Health).

Key Points: 
  • LEXINGTON, Mass., Nov. 7, 2022 /PRNewswire/ -- Hemanext Inc ., a leading innovator in blood processing, storage, and transfusion technology, today announcedthe successful firstclose of its Series B fundraising round.
  • Taken together with the exercise of outstanding warrants, this close bringsan additional $18 millionof equity capitalfromnoted globalprivate investorswithdeepfinance and healthcare expertise.
  • To date, the company has raised approximately $130mm (inclusive of $8mm in grant funding from the National Institutes of Health).
  • The Companywill be keepingthe current Series B available to investors for thenext few weeks.Hemanextexpects to begin a Series C roundwithinstitutional investorsin 2023.

Gurnet Point Capital Appoints Stacey Seltzer as Partner

Retrieved on: 
Thursday, November 3, 2022
General Health, Professional Services, Health, Finance, Therapy, Multimedia, Board, Industry, Gurnet Point, Massachusetts, Patient, Partner, Marketing, GPC, Wharton School of the University of Pennsylvania, MBA, Schering-Plough, Biochemistry, Fine chemical, Yale University

Gurnet Point Capital ("Gurnet Point), a private investment firm focused on the healthcare sector that is part of the B-FLEXION group of investment partnerships and direct holdings, today announced the appointment of Stacey Seltzer as a new Partner to further strengthen the firms management team.

Key Points: 
  • Gurnet Point Capital ("Gurnet Point), a private investment firm focused on the healthcare sector that is part of the B-FLEXION group of investment partnerships and direct holdings, today announced the appointment of Stacey Seltzer as a new Partner to further strengthen the firms management team.
  • View the full release here: https://www.businesswire.com/news/home/20221103005593/en/
    An experienced life sciences investor, Ms. Seltzer most recently served as Partner at Aisling Capital, where she led or co-led more than 15 transactions with growth-stage life science companies.
  • At Gurnet Point, she will source deals and lead transactions across the therapeutics space.
  • Gurnet Point Capital is a leading healthcare fund that invests in de-risked life sciences companies.

"What Makes a Successful General Counsel Today:" The Vanguard Forum for General Counsels - December 8 and 9 in NYC

Retrieved on: 
Saturday, November 5, 2022
Leadership, Success, Forum, ESG, Turnaround management, Board, GC, Vanguard, The Vanguard Group, CEO, GCS, General counsel, HBR, Dentons, Schering-Plough, Chief executive officer, Public policy, Solution, Public relations, Perfume, Nightclub, Management, Tenneco, United Airlines, Walgreens

NEW YORK, Nov. 5, 2022 /PRNewswire-PRWeb/ -- General Counsels from all industries across the US will gather in New York City for https://www.thevanguardnetwork.com annual GC Forum on December 8 and 9. The theme reflects the changing and expanding role of chief legal officers: "What Makes a Successful GC Today."

Key Points: 
  • The Vanguard Forum is an opportunity for these senior executives to share real-world challenges and craft solutions.
  • The theme reflects the changing and expanding role of chief legal officers: "What Makes a Successful GC Today."
  • Chairing the Vanguard Forum are legendary GCs Tom Sabatino, currently with Tenneco; Mary Ann Hynes, now with Dentons, and David Robinson of The Hartford.
  • This will be the first time that Vanguard members and other GCs will gather in person for the Forum since 2020.

World's Largest Veterinary Meeting & Expo Celebrates 40 Years of Advances in Veterinary Medicine, Looks Ahead to Next Great Innovations

Retrieved on: 
Wednesday, October 26, 2022
Sentinel, Quality of life, Veterinarian, Schering-Plough, Surgical management of fecal incontinence, Animal bite, VMX, Diagnosis, Dermatology, Animal, Cardiology, Routine, CAE, Sentinel (comics), Ortho, Neoplasm, Orange County Convention Center, Hill's Pet Nutrition, Intelligence, General officer, American Veterinary Medical Association, Publication, Dog, The New York Times, PETS, Multimedia, STEM, Cancer, The Sunday Times Magazine, Student, Continuing education, Google Images, Family medicine, Track, Behavior, Neurology, Orlando Sentinel, Veterinary medicine, TIME, Boehringer Ingelheim, Golden Globe Awards, Guinea pig, Mindfulness, Hill, Hedgehog, DVM, Time (magazine), B cell, Rabbit, Pain

ORLANDO, Fla., Oct. 26, 2022 /PRNewswire/ -- From diagnostic imaging to detect tumors in aquatic animals, to doubling the lifespan of dogs, the last 40 years have brought remarkable breakthroughs in veterinary medicine that have transformed the diagnosis, treatment and quality of life of animals of all kinds. The global leader in continuing education for veterinary professionals, the North American Veterinary Community (NAVC), will mark four decades of innovative veterinary  education at its 40th annual Veterinary Meeting & Expo (VMX), Jan. 14 to 18, 2023 in Orlando, FL at the Orange County Convention Center. VMX 2023 will continue the tradition of helping animals of all kinds live longer, better lives while looking ahead to tomorrow's advancements by providing veterinary professionals from all over the world hundreds of education sessions and many hands-on workshops conducted by the world's most renowned animal healthcare experts. 

Key Points: 
  • Dog life expectancy has doubled in the past 40 years, and house cats now live twice as long as their feral counterparts.
  • "Dog life expectancy has doubled in the past four decades, and house cats now live twice as long as their feral counterparts.
  • Since its first conference, VMX has grown to become the world's largest and most comprehensive global veterinary education event.
  • The North American Veterinary Community (NAVC) is a nonprofit organization dedicated to supporting and advancing veterinary professionals worldwide.

SomaLogic Announces the Appointment of Biotech Veteran Troy Cox as Executive Chairman of the Board of Directors

Retrieved on: 
Monday, October 17, 2022
SAN, Proteomics, Therapy, Growth, UCB, NASDAQ, Roche, Foundation Medicine, SomaLogic, Nasdaq, Senior, Acquisition, Schering-Plough, Board, CEO, Health, Chair, GLOBE, Sanofi, Leadership, Management, Genentech

BOULDER, Colo. and SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today announced the appointment of current board member and biotech veteran Troy Cox as Executive Chair to the companys Board of Directors.

Key Points: 
  • BOULDER, Colo. and SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today announced the appointment of current board member and biotech veteran Troy Cox as Executive Chair to the companys Board of Directors.
  • Mr. Cox brings over thirty years of experience in the life sciences and biopharmaceuticals industry to his expanded position as Executive Chair of the Board.
  • Mr. Cox was the President and CEO of Foundation Medicine from early 2017 through the acquisition by Roche, valuing Foundation Medicine at $5.3 billion.
  • We are very pleased to appoint Mr. Cox as Executive Chair of SomaLogics Board of Directors, said SomaLogic Chief Executive Officer Roy Smythe, M.D.

Global Flea and Tick Product Market Report (2022 to 2031) - Industry Analysis, Size, Share, Growth, Trends and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 19, 2022
Pets, Consumer, CAGR, Government, Merck, Internet, Schering-Plough, Merck & Co., Research, SWOT, Pharmaceutical industry

The report also provides the compound annual growth rate (CAGR %) of the global flea and tick product market from 2022 to 2031.

Key Points: 
  • The report also provides the compound annual growth rate (CAGR %) of the global flea and tick product market from 2022 to 2031.
  • Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global flea and tick product market.
  • Moreover, the report sheds light on the changing competitive dynamics in the global flea and tick product market.
  • Company overview, financial standings, recent developments, and SWOT are attributes of players in the global flea and tick product market profiled in this report.

Patrick Healy, a Senior Biopharma Executive with a Successful Track Record in Clinical Trials Development, joins Aviceda Therapeutics as Chief Operations Officer

Retrieved on: 
Monday, October 17, 2022
Technology, Research, Nanotechnology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Science, Immunology, NHP, Disease, Therapy, MOA, Macrophage, Population, Geographic atrophy, IgG4-related ophthalmic disease, Pfizer, GA, Retina, Roche, Patient, Drug development, Program, Aviceda, Senior, Technology, Eye, Industry, DRS, CNV, Microglia, Schering-Plough, Neurology, CEO, Safety, Clinical trial, CMO, Phase, Corporate title, FDA, Internet, Q12, AMD, Pharmaceutical industry, Fine chemical, Ophthalmology, IND, Fibrosis

Mr. Healy is joining Aviceda as Chief Operations Officer and Senior Vice-President.

Key Points: 
  • Mr. Healy is joining Aviceda as Chief Operations Officer and Senior Vice-President.
  • Mohamed Genead (CEO), David Callanan (CMO), Michael Tolentino (Chief Technology Officer), Tarek Hassan (Chief Development Officer), Derek Kunimoto (Chief Strategy Officer) and Christopher Scott (Chief Scientific Officer), leaders in the field.
  • At Trial Runners, Mr. Healy has overseen over 90 ophthalmology clinical trials, having engaged with more than 17,000 patients.
  • Aviceda is focusing its efforts on commencing its clinical trial for its lead product, AVD-104 for GA secondary to dAMD.